Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    The Case of the Cord Blood Match
    Clinical practice
    The Case of the Cord Blood Match
    March 26, 2021
    Empower Recent Graduate Nurses to Be Patient Advocates
    Nurse empowerment
    Empower Recent Graduate Nurses to Be Patient Advocates
    March 19, 2021
    Shared Governance Committees Empower Nurses to Use Their Voice
    Nurse empowerment
    Shared Governance Committees Empower Nurses to Use Their Voice
    March 12, 2021
    Nursing Students Connect Beyond the Classroom With ONS Resources
    Nursing education
    Nursing Students Connect Beyond the Classroom With ONS Resources
    March 05, 2021
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatment side effects

    Manage Adverse Events From PI3K Inhibitors for Breast Cancer
    Breast cancer

    Manage Adverse Events From PI3K Inhibitors for Breast Cancer

    In 2019, PI3K inhibitors became a new treatment option for postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer with the U.S. Food and Drug Administration’s approval of alpelisib in combination with fulvestrant. Although alpelisib remains the only PI3K inhibitor approved today, others are in clinical trials, and the new class of agents has a unique safety profile.

    March 09, 2021
    Be Alert for Axillary Adenopathy After COVID-19 Vaccination
    COVID-19

    Be Alert for Axillary Adenopathy After COVID-19 Vaccination

    Nearly 60 million people in the United States and almost 200 million around the world have received the COVID-19 coronavirus vaccine as of mid-February 2021, and the numbers will continue to grow as more doses come to market and other manufacturers’ versions receive emergency use authorizations. As more people get vaccinated, some of the expected side effects are being observed in clinical practice and have implications for cancer care. 

    February 19, 2021
    FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Myelosuppression
    Chemotherapy

    FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Myelosuppression

    On February 12, 2021, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela™) as the first therapy in its class to reduce the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. Trilaciclib inhibits cyclin-dependent kinase 4/6 (CDK 4/6) enzymes to prevent bone marrow damage.   

    February 15, 2021
    Targeted Radiation Reduces Pain From Spine Metastasis
    Research

    Targeted Radiation Reduces Pain From Spine Metastasis

    Palliative radiation targeted directly to the tumor with stereotactic body radiation therapy eliminated metastatic pain in 33% of patients for six months compared to 16% with standard radiation therapy. Researchers reported the study findings at the American Society for Radiation Oncology annual meeting.

    February 10, 2021
    The Case of the Targeted Therapy Toxicities
    Clinical practice

    The Case of the Targeted Therapy Toxicities

    Three years ago, Tony, a 42-year-old man, began FOLFOX chemotherapy treatment for stage III colon cancer and achieved a complete response. Two years later, a biopsy of an intraabdominal lesion uncovered metastatic disease, and he was prescribed the epidermal growth factor inhibitor (EGFRi) cetuximab. Alex, the oncology nurse educating Tony on the side effects of EGFRi therapy, understands that skin toxicities are common with the class of drugs and looks for national guidelines for prevention and management direction.

    January 19, 2021
    Manage Cancer Treatment-Related Radiodermatitis With ONS Guidelines™
    Clinical practice guidelines

    Manage Cancer Treatment-Related Radiodermatitis With ONS Guidelines™

    Painful skin reactions may develop in as many as 95% of patients receiving radiotherapy treatments for cancer. Patients report that it affects their quality of life and that purchasing interventions to soothe their skin increases their out-of-pocket costs. Supporting patients who experience the side effect is critical for their well-being.

    January 12, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects

    The Case of Concurrent Therapy Concerns

    Sharon is a 60-year-old woman with metastatic breast cancer that was originally diagnosed in 2005 and treated with a mastectomy, deep inferior epigastric artery perforator flap reconstruction, chemotherapy, post mastectomy radiation, and five years of tamoxifen. Three months ago, her breast cancer recurred, and staging scans demonstrated metastatic disease in the lungs, left axilla, liver, and left iliac bone. A biopsy of the left iliac bone was ER positive, PR negative, and HER2 negative. Sharon began treatment with radiation to the painful left hip and letrozole, with the plan to start palbociclib once radiation was completed. 

    December 18, 2020
    Manage Cancer Treatment-Related Constipation With ONS Guidelines™
    Clinical practice guidelines

    Manage Cancer Treatment-Related Constipation With ONS Guidelines™

    As many as 43%–58% of patients with cancer experience constipation related to their treatment, and the side effect is both distressing and potentially life threatening if severe enough. Constipation-related emergency department visits increased by 41.5% from 2006–2011, with older adults (aged 85 years or older) making up most of the visits. Estimates suggest that the cost of managing severe cancer-related constipation may range from $500 to more than $2,300 per person per month. Supporting patients who experience the side effect is critical for their well-being.

    December 08, 2020
    Pancreatic Cancer Risk Factors, Diagnosis, Treatment, Side Effects, and Survivorship Considerations
    Pancreatic cancer

    Pancreatic Cancer Risk Factors, Diagnosis, Treatment, Side Effects, and Survivorship Considerations

    Pancreatic cancer is the ninth most common cancer in the United States, accounting for 3% of all cancers but causing 7% of cancer-related deaths, which equates to about 57,500 diagnoses and 47,050 deaths each year. The average person’s risk for pancreatic cancer is about 1 in 64.

    December 03, 2020
    The Case of the Chronic Cancer Condition
    Clinical practice

    The Case of the Chronic Cancer Condition

    Lisa, a 32-year-old tax accountant, completed treatment for stage III triple-negative breast cancer 18 months ago. During a follow-up appointment, Lisa reported worsening headaches and difficulty concentrating at work. A magnetic resonance imaging scan and subsequent biopsy revealed a solitary brain lesion. She completed stereotactic brain radiation two months ago.

    November 16, 2020
    Manage Cancer Treatment-Related Skin Toxicities With ONS Guidelines™
    Clinical practice

    Manage Cancer Treatment-Related Skin Toxicities With ONS Guidelines™

    From chemotherapy to immunotherapy, many of today’s cancer treatments are associated with skin toxicities. Left unmanaged, they can affect patients’ activities of daily living, self-image, and overall quality of life and may lead to treatment disruptions, delays, or even discontinuation.

    November 10, 2020
    The Case of the Terrible Taste
    Chemotherapy

    The Case of the Terrible Taste

    Tanya is a 46-year-old woman with leukemia. She recently finished induction therapy, and her oncologist told her she is ready to receive a hematopoietic stem cell transplant. You speak with Tanya about what to expect in the upcoming weeks before her transplant, but she interrupts you: “Nothing tastes good anymore. I am so scared because I thought I completed chemotherapy. The doctor just told me I have to get more before my transplant. Every time I get chemotherapy, I lose my appetite.”

    November 06, 2020
    Manage Malnutrition’s Monstrous Consequences in Patients With Cancer
    Treatment side effects

    Manage Malnutrition’s Monstrous Consequences in Patients With Cancer

    Nutritional status is one aspect of cancer care that may often be overlooked. Patients, particularly those with esophageal, gastric, pancreatic, and non-small cell lung cancers, have increased nutritional requirements because of their high resting energy expenditure. Treatment side effects further hinder a patient’s desire and ability to eat, creating a wider gap between energy intake and energy needs and placing patients with cancer at high risk for malnutrition.

    October 16, 2020
    Manage Cancer Treatment-Related Lymphedema With ONS Guidelines™
    Treatment side effects

    Manage Cancer Treatment-Related Lymphedema With ONS Guidelines™

    Surgical treatment for breast, gynecologic, prostate, lymphoma, melanoma, or head and neck cancers puts patients at risk for developing secondary lymphedema at any point in the remainder of their life. Studies show that as many as 10%–40% of patients with breast cancer may experience breast cancer–related lymphedema. 

    October 13, 2020
    Help AYA Survivors and Patients With Cancer Navigate Infertility
    Patient empowerment

    Help AYA Survivors and Patients With Cancer Navigate Infertility

    In part thanks to advancements in both cancer treatment and supportive care, the number of cancer survivors is expected to reach 22 million by 2030. Adolescent and young adult (AYA) patients aged 15–39 constitute only 5% of new cancer diagnoses but have an 85% relative five-year survival rate. They represent a significant portion of all current and future cancer survivors and have unique needs, including reaching developmental milestones, coping with disruptions in personal and professional relationships, and encountering potential difficulties in family planning.  

    October 02, 2020
    Non-Hodgkin Lymphoma Symptoms, Diagnosis, Treatment, and Survivorship Recommendations
    Clinical practice

    Non-Hodgkin Lymphoma Symptoms, Diagnosis, Treatment, and Survivorship Recommendations

    Lymphomas are hematologic malignancies, specifically of the lymphatic system. They are classified into two types: Hodgkin and non-Hodgkin (NHL). NHL is the seventh most common cancer in the United States and Hodgkin seen much less frequently as the 26th, but new treatment options have improved survival rates.

    September 29, 2020
    ONS Guidelines™ Offer Framework for Managing Treatment-Related Hot Flashes
    Treatment side effects

    ONS Guidelines™ Offer Framework for Managing Treatment-Related Hot Flashes

    Because of treatment effects on hormones, women with breast cancer and men with prostate cancer have an increased risk of frequent and severe hot flashes after treatment. As many as 80% of patients across both genders experience the symptom, which can have an impact on sleep, mood, energy, and sexual function.

    September 10, 2020
    The Case of the Major Malnutrition Concerns
    Oncology nurse education

    The Case of the Major Malnutrition Concerns

    Max, a 60-year-old patient with head and neck cancer, is receiving chemoradiation. Since his initial consult, he’s experienced a 12% weight loss from baseline, impaired swallowing, pain, anorexia, and dysgeusia. He has financial challenges, limited social support, poor health literacy, and a history of alcohol abuse. He has a feeding tube, but you suspect he is not using it. You reinforce prior education about malnutrition, and although Max refuses to be admitted to the hospital, he promises to do better.

    August 21, 2020
    Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations
    Treatment side effects

    Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations

    Glioblastoma or glioblastoma multiform (GBM) is a primary central nervous system tumor. Approximately 23,890 new brain tumors are diagnosed in the United States each year, with GBM accounting for 38%. GBM can present as a primary diagnosis or evolve from a lower grade brain tumor.

    August 06, 2020
    Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization
    Chemotherapy

    Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization

    Patients who take five or more medications in the six months before beginning IV chemotherapy for a cancer diagnosis are more likely to be hospitalized after their chemotherapy treatment, according to the findings from a new study published in the Journal of Geriatric Oncology.

    June 19, 2020
    Exercise Before ADT Treatment Reduces Rate of Side Effects
    Cancer research

    Exercise Before ADT Treatment Reduces Rate of Side Effects

    Beginning a supervised exercise program before the start of androgen deprivation therapy (ADT) for prostate cancer reduced the incidence of treatment-related side effects, researchers reported in a study published in BJU International.

    June 17, 2020
    Pelvic Radiation May Decrease Bone Mineral Density
    Radiation therapy

    Pelvic Radiation May Decrease Bone Mineral Density

    Women receiving pelvic radiation therapy for gynecologic cancers are at higher risk for significant decreases in bone mineral density (BMD), with 7.8% of women in the study diagnosed with a pelvic fracture, according to findings from a study published in Cancer.

    June 10, 2020
    Proton Therapy May Reduce Radiation’s Severe Side Effects
    Radiation therapy

    Proton Therapy May Reduce Radiation’s Severe Side Effects

    Proton beam radiation therapy is safer and equally effective as traditional radiation for adults with advanced cancers, researchers reported in study findings in JAMA Oncology.

    May 27, 2020
    The Case of the Medication Modification
    Treatment side effects

    The Case of the Medication Modification

    Doug is a 70-year-old man receiving treatment at the cancer center for metastatic renal cell carcinoma. He was initially treated with sunitinib, a tyrosine kinase inhibitor (TKI). He has been experiencing significant upper back pain and is having trouble with fine motor skills in his fingers. The oncologist, suspecting spinal cord compression (SCC), ordered a computed tomography scan, which confirmed metastatic lesions in the spine leading to instability and mild SCC. The oncologist refers Doug for surgery and advises him that a new medication, cabozantinib, will be ordered for after his surgery. The oncologist asks you, the oncology nurse, to instruct Doug on surgical preparations and educate him on cabozantinib.

    May 19, 2020
    How to Prevent Opioid Misuse While Effectively Managing Cancer Pain
    Pain management

    How to Prevent Opioid Misuse While Effectively Managing Cancer Pain

    Opioid misuse is prevalent among the U.S. population—so much so that President Trump declared it a public health emergency in 2017. At the same time, research shows that 20%–50% of patients with cancer and 80% of those with advanced-stage disease report experiencing moderate to severe pain. Balancing the dichotomies is difficult, but oncology nurses and other cancer care providers have a responsibility to provide comprehensive pain management for patients with cancer.

    May 12, 2020
    Remodeled CAR T-Cell Therapy May Reduce Side Effects
    Cancer treatments

    Remodeled CAR T-Cell Therapy May Reduce Side Effects

    A new type of remodeled CAR T-cell treatment is just as effective as the original therapy but may result in fewer neurologic side effects, researchers reported in Nature Medicine.

    May 06, 2020
    The Case of the Cryotherapy Consequences
    Cancer treatments

    The Case of the Cryotherapy Consequences

    Janice is 32 years old and was recently diagnosed with triple-negative breast cancer. She is receiving neoadjuvant chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel. Janice is a nationally recognized performer (vocal and piano) and is distraught over the possibility of losing her hair or developing chemotherapy-induced peripheral neuropathy and mouth sores. She asks the nurse what can be done to prevent those unwanted side effects.  

    April 14, 2020
    Radiation Unnecessary for Children With ALL
    Radiation therapy

    Radiation Unnecessary for Children With ALL

    Children with acute lymphoblastic leukemia (ALL) at risk for cancer recurrence in the brain don’t need prophylactic radiation therapy, researchers reported in the Journal of Clinical Oncology. 

    March 18, 2020
    Abandoning E-Cigarettes; Lymphedema Bill Stalls; Global Cancer Cases
    U.S. Food and Drug Administration (FDA)

    Abandoning E-Cigarettes; Lymphedema Bill Stalls; Global Cancer Cases

    Vaping pens and other electronic smoking devices were branded as step-down strategies to help the 60 million Americans who are unable to quit traditional cigarettes. The U.S. Food and Drug Administration even supported the idea initially, but research eventually showed that vaping products contain the same or higher levels of nicotine as other tobacco products and are equally as addictive.

    February 24, 2020
    Does Cryotherapy Prevent Extremity Toxicities From Taxane Chemotherapy?
    Treatment side effects

    Does Cryotherapy Prevent Extremity Toxicities From Taxane Chemotherapy?

    As many as 50% of patients receiving taxane chemotherapy have reported experiencing peripheral neuropathy (PN) or nail changes during treatment. Both are potentially dose-limiting adverse events: nail changes can lead to infections; PN affects patients’ ability to perform activities of daily living and results in sensory impairments such as loss of balance, muscle weakness, and numbness that can increase patients’ risk for falls.

    January 07, 2020
    How Can Oncology Nurses Collaborate With Dietitians to Manage Malnutrition?
    Treatment side effects

    How Can Oncology Nurses Collaborate With Dietitians to Manage Malnutrition?

    Nutrition impact symptoms (NIS) involve any barrier to a patient’s nutritional status. Cancer and its treatments often lead to complex side effects that develop rapidly and change in character and intensity throughout treatment. Barriers to eating and drinking, digesting, and absorbing nutrients lead to negative clinical outcomes for patients with cancer, including malnutrition. Prompt assessment and interventions are key to helping patients avoid treatment holidays and dose reductions while also promoting the best possible quality of life during their cancer journey. In fact, a weight loss of just 5% is an indicator that a patient will likely not receive all of his or her prescribed cancer treatment.

    November 05, 2019
    Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents
    Advanced practice nursing (APN)

    Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents

    As a side effect of cancer or its treatment, anemia is associated with reduced quality of life, thanks to symptoms such as palpitations, fatigue, dyspnea, and dizziness. Etiology is often multifactorial with contributing factors such as suppression of hematopoiesis from malignancy or cancer treatments, bleeding, nutritional deficiencies, renal insufficiency, or hemolysis.

    October 31, 2019
    Vaping Tax; Expensive Compression Garments; ACA Premiums Fall
    Cancer risk factors

    Vaping Tax; Expensive Compression Garments; ACA Premiums Fall

    The rise in youth vaping has cemented e-cigarettes as a scourge of the tobacco cessation community. The products have been marketed to minors, and Congress is currently reviewing several bills meant to tackle the issue. A House of Representatives panel agreed to levy a new vaping tax on e-cigarette pods, an effort that would raise prices for vaping products in the hopes of making them less appealing and accessible to teens. Even in today’s politicized and divisive environment, bipartisan consensus demonstrates that something must be done at the federal level to combat the increase in underage smoking, particularly with electronic devices.

    October 28, 2019
    Pneumonitis With Immunotherapy Treatment
    Immunotherapy

    Pneumonitis With Immunotherapy Treatment

    Pneumonitis is inflammation of the lung parenchyma; although rare, it can be fatal. Nishino et al. found that the overall incidence of pneumonitis with PD-1 inhibitor monotherapy was 2.7% for all-grade and 0.8% for grade 3 or higher pneumonitis. Naidoo et al. reported an approximate 5% incidence of all-grade pneumonitis, although the incidence of all-grade pneumonitis is higher with combination immunotherapy (up to 10%). The incidence is more common with higher grades in PD-1 inhibitors (versus PD-L1 inhibitors), but it occurs less often with anti-CTLA4 monoclonal antibodies. 

    September 23, 2019
    Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding
    Research

    Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding

    Patients with hematologic cancers have a 19% increased risk for blood clots or bleeding events even 10 years after diagnosis, according to the results of a study published in the Journal of Thrombosis and Haemostasis.

    September 11, 2019
    Acupuncture for Cancer-Related Fatigue
    Complementary therapy

    Acupuncture for Cancer-Related Fatigue

    Fatigue is one of the most prevalent and challenging side effects that people with cancer experience. Commonly known as cancer-related fatigue (CRF), the National Comprehensive Cancer Network  defines it as “a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning.” CRF affects 50%–90% of patients and can diminish quality of life, lead to functional impairment, and is associated with significant morbidity. Although it improves in many patients the year following treatment, CRF may persist over a much longer period in some.

    May 14, 2019
    ONS Congress

    Patient Comfort Is Key to Managing Radiation Side Effects

    Radiation therapy may cause traumatic side effects in patients with cancer, yet many standard management strategies lack strong evidence. During their session at the ONS 44th Annual Congress in Anaheim, CA, Renata Benc, RN, BA, MSc(A), CON(C), of Jewish General Hospital of the Integrated Health and Social Services University Network for West-Central Montréal in Quebec, Canada, and John Hillson, RN, BSN, BA, OCN®, of Duke Cancer Institute in Durham, NC, instructed nurses on how to support patients undergoing radiation treatment.

    April 11, 2019
    For Oxaliplatin Hypersensitivity Reactions, Prevention Is the Best Strategy, but Here’s How to Manage Them
    Adverse events

    For Oxaliplatin Hypersensitivity Reactions, Prevention Is the Best Strategy, but Here’s How to Manage Them

    As the use of oxaliplatin in the treatment of gastrointestinal, gynecologic, and other cancers continues to grow, so too does the incidence of hypersensitivity reactions connected to the drug. Because the development of HSRs may require patients to discontinue oxaliplatin even if it’s effective against their cancer, oncology nurses need to be able to prevent or minimize reactions whenever possible.

    April 09, 2019
    Understand the Evidence for Exercise in Gynecologic Cancer-Related Fatigue
    Treatment side effects

    Understand the Evidence for Exercise in Gynecologic Cancer-Related Fatigue

    Cervical cancer is the fourth most common cancer in women and the seventh most common overall. Cancer-related fatigue (CRF) has an estimated prevalence of 50%–90% in all patients and has been reported to affect 17%–33% of women with gynecologic cancers for as long as three to eight years after diagnosis. Many national guidelines from organizations such as the American College of Sports Medicine, American Cancer Society, National Institute for Health and Care Excellence, and ONS all recommend exercise to improve fatigue in patients with cancer. But no research has synthesized the evidence for exercise as an intervention for fatigue specifically in patients with gynecologic cancers. 

    March 12, 2019
    Be Alert for Severe, Early-Onset Toxicities From 5-Fluorouracil and Capecitabine
    Clinical practice

    Be Alert for Severe, Early-Onset Toxicities From 5-Fluorouracil and Capecitabine

    Although 5-fluorouracil (5-FU) and capecitabine (the oral prodrug of 5-FU) are generally well tolerated, patients can experience severe toxicities from either drug that can be life-threatening if not treated quickly. Of the 275,000 patients who receive 5-FU each year, more than 1,300 die from 5-FU toxicity, or approximately 3–4 patients per day.

    February 12, 2019
    San Antonio Breast Cancer Symposium

    Glutathione Plays a Role in Treatment-Related CINV

    Chemotherapy-induced nausea and vomiting (CINV) can negatively affect nutritional intake, ability to work, and treatment adherence. Research suggests that younger age and female gender are the strongest predictors of CINV, but those may not be the only factors, particularly for delayed nausea, according to research findings presented at the San Antonio Breast Cancer Symposium on December 5, 2018.

    December 13, 2018
    JADPRO Live

    Nutritional Support Reduces Weight Loss for Patients With Head and Neck Cancer

    As many as 50% of patients with head and neck cancer experience pretreatment weight loss. In addition, treatment frequently involves chemotherapy and radiation, which can also result in weight loss, as well as mucositis and dysphagia, which can affect patients’ ability to eat. This could lead to treatment delays that may impact treatment efficacy.

    November 13, 2018
    Dems on Health Care; Obamacare Enrollment; Pricey Precision Medicine
    Affordable Care Act (ACA)

    Dems on Health Care; Obamacare Enrollment; Pricey Precision Medicine

    To Rally Voters, Democrats Focus on Health Care as Their Closing Argument

    Although many states are already collecting early votes, Tuesday, November 6, 2018, will tell the full tale of the midterm elections. Many Democrats are emphasizing their focus on health care in the final days and hours before the election. By most measurable public opinion poll, health care remains the most important domestic issue for voters.

    November 05, 2018
    Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab
    Clinical practice

    Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab

    Monoclonal antibody cancer treatments such as rituximab have a high risk for hypersensitivity reactions from cytokine release syndrome. The symptoms, which can range from mild to life threatening, result from tumor antigen-expressing cells releasing cytokines (e.g., tumor necrosis factor, interleukin, interferon) into the blood as they are destroyed. Symptoms include fever, chills, rigors, rash, headache, hypotension, shortness of breath, bronchospasm, nausea, vomiting, and abdominal pain.

    October 09, 2018
    What Oncology Nurses Need to Know About Tumor Lysis Syndrome
    Oncologic emergencies

    What Oncology Nurses Need to Know About Tumor Lysis Syndrome

    Tumor lysis syndrome is an oncologic emergency caused by massive tumor cell death with the release of large amounts of potassium, phosphate, and nucleic acids into systemic circulation. Nucleic acids break down to uric acid, leading to hyperuricemia in patients. This, in turn, leads to precipitates in the renal tubules, renal vasoconstriction, decreased renal flow, inflammation, and can potentially cause acute kidney injury. 

    October 02, 2018
    The Case of the CAR T-Cell Toxicity Test
    Clinical practice

    The Case of the CAR T-Cell Toxicity Test

    Wilson was diagnosed with B-cell lymphoma three days after his 63rd birthday. He underwent chimeric antigen receptor (CAR) T-cell therapy after his disease failed to respond to two lines of systemic chemotherapy.

    September 18, 2018
    NINR Study Identifies Genes for Fatigue in Cancer Treatment
    Genetics & genomics

    NINR Study Identifies Genes for Fatigue in Cancer Treatment

    Radiation therapy can be an incredibly draining form of treatment for patients with cancer. Side effects such as fatigue can be debilitating for many before, during, and after treatment. Because symptom management is a crucial component to cancer care and central role of oncology nursing, ensuring that patients are able to mitigate their symptoms and side effects can help improve their quality of life. Recently, a team at the National Institute of Nursing Research (NINR) identified certain genes associated with fatigue in men being treated for prostate cancer.

    August 29, 2018
    ONS Congress

    Nurses Share New Ways to Prevent and Manage Difficult Side Effects in Cancer Care

    Managing toxicities and adverse events (AEs) so that patients can continue to stay on effective treatments is essential to improving outcomes. Catherine Hill, BSN, RN, OCN®, Margaret Blaney, RN, BSN, Ashley Layton, BSN, RN, OCN®, and Kaddie Lopez, BSN, RN, OCN®, PHN, discussed ways to manage and prevent symptoms in cancer care during a session at the 43rd Annual Congress in Washington, DC.

    July 18, 2018
    APRNs Can Help Address Global Financial Toxicity
    Advanced practice nursing (APN)

    APRNs Can Help Address Global Financial Toxicity

    Advancements in oncology, such as new diagnostic tools and novel therapies, have improved overall survival rates but have come at a high cost. In 2011, targeted therapies accounted for 63% of all chemotherapy expenditures. A novel cancer drug routinely costs each patient more than $100,000 per year; annual spending on cancer drugs is globally estimated around $100 billion U.S. dollars and is predicted to rise to $150 billion by 2020.

    June 14, 2018
    Here’s an Overview of the Types, Mechanisms, and Side Effects of Currently Approved Immunotherapies
    Immunotherapy

    Here’s an Overview of the Types, Mechanisms, and Side Effects of Currently Approved Immunotherapies

    Immunotherapy drugs fall into varying classes, each carrying its own mechanism of action and anticipated side effects. Although some side effects of immunotherapy may appear similar to those of chemotherapy (e.g., diarrhea, fatigue), they actually result from a totally different mechanism—meaning they require a different approach to management. Treating immunotherapy side effects as you would chemotherapy effects would likely result in patient harm.

    May 29, 2018
    • Current page 1
    • Page 2
    • Page 3
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲